Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Income towards Parent Company: 2020-2024

Historic Income towards Parent Company for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to -$195.9 million.

  • Prime Medicine's Income towards Parent Company fell 0.60% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.6 million, marking a year-over-year increase of 8.97%. This contributed to the annual value of -$195.9 million for FY2024, which is 1.14% up from last year.
  • Per Prime Medicine's latest filing, its Income towards Parent Company stood at -$195.9 million for FY2024, which was up 1.14% from -$198.1 million recorded in FY2023.
  • Prime Medicine's Income towards Parent Company's 5-year high stood at -$3.4 million during FY2020, with a 5-year trough of -$198.1 million in FY2023.
  • For the 3-year period, Prime Medicine's Income towards Parent Company averaged around -$171.9 million, with its median value being -$195.9 million (2024).
  • Per our database at Business Quant, Prime Medicine's Income towards Parent Company crashed by 4,702.58% in 2021 and then increased by 26.33% in 2022.
  • Prime Medicine's Income towards Parent Company (Yearly) stood at -$3.4 million in 2020, then slumped by 4,702.58% to -$165.4 million in 2021, then climbed by 26.33% to -$121.8 million in 2022, then crashed by 62.64% to -$198.1 million in 2023, then increased by 1.14% to -$195.9 million in 2024.